基于免疫检查点阻塞的治疗后与免疫相关的不良事件与高级肉瘤中改善的生存率有关
Evan Rosenbaum1,2, Kenneth Seier3, Martina Bradic4
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer research communications
|October 3, 2023
概括
在接受免疫检查点阻塞 (ICB) 治疗的肉瘤患者中,与免疫相关的不良事件 (irAE) 与改善整体存活率和更炎症的瘤微环境有关. 这表明irAEs可能表明较强的抗瘤免疫反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 与免疫相关的不良事件 (irAE) 在接受免疫检查点阻塞 (ICB) 治疗的患者中很常见.
- 在接受ICB治疗的肉瘤患者中,IREs对结果的影响尚不清楚.
研究的目的:
- 为了研究与ICB治疗的晚期肉瘤患者的irAEs和生存结果之间的关联.
- 探索与irAE发展相关的瘤组织中的潜在免疫相关生物标志物.
主要方法:
- 对131名接受ICB治疗的晚期肉瘤患者的回顾性审查.
- 使用考克斯回归的生存分析,以irAE发生为时间依赖的共变量.
- 瘤样本的RNA测序,以确定具有和没有irAEs的患者的差异性基因表达模式.
主要成果:
- 32%的患者至少经历过一次IRAE;12%的患者有3级或以上的IRAE.
- irAE与显著改善的整体存活时间 (OS) 相关 (HR,0.443;P = 0.007).
- 观察到改善无进展生存 (PFS) 的趋势 (HR,0.662;P = 0.074).
- 患有irAEs的患者表现出瘤透免疫细胞 (树突细胞,CD8+ T细胞,调节性T细胞) 的基线水平较高,以及免疫/炎症通路的升调.
结论:
- 在肉瘤患者接受ICB治疗后的irAEs与改善的整体存活率有关.
- 存在irAEs可能表明更强大的抗瘤免疫反应,反映在基线的炎症瘤微环境中.
更多相关视频
07:15A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.6K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.2K
相关概念视频
01:27Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
01:21Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K